Abstract
Lycorine, a natural alkaloid extracted from the Amaryllidaceae plant family, has been reported to exhibit a wide range of physiological effects, including the potential effect against cancer. However, the anti-prostate cancer (PCa) efficacy of Lycorine remains unrevealed. In this context, we figured out Lycorine's anti-proliferative and anti-migratory properties for PCa treatment. Lycorine inhibited proliferation of various PCa cell lines, induced cell apoptosis and cell death. Here we showed that Lycorine decreased proliferation, migration, invasion, survival and EMT of prostate cancer cell lines. Subcutaneous and orthotopic xenotransplantations by ectopic implantation of the human hormone-refractory PC-3M-luc cells were used to confirm in vivo anticancer effects of Lycorine. Lycorine inhibited both growth and metastasis in multiple organs (liver, lung, kidney, spleen and bone) in vivo and improved mice survival. Lycorine prevented EGF-induced JAK/STAT signaling. Importantly, anti-cancer effects of Lycorine were dependent on STAT expression. We suggest that Lycorine is a potential therapeutic in prostate cancer.
Highlights
Prostate cancer (PCa) is the principle malignant tumor threatening the health of senile male all over the world
We present that Lycorine inhibits proliferation, migration, invasion and survival of various PCa cell lines, induces cell apoptosis and cell death, and reverses epithelial mesenchymal transition (EMT) process of prostate cancer cell lines
Men with hormone-refractory PCa are at high risk for developing distant metastasis, which results in clinically significant disability and mortality [32]
Summary
Prostate cancer (PCa) is the principle malignant tumor threatening the health of senile male all over the world. According to the latest statistics, PCa accounts for 27% of all cancer incidences and ranks the second leading cause of cancer-related mortality among men in the US [1]. It is estimated that by January 1, 2024, the whole cancer survivors in American will increase to nearly 19 million and PCa will still be the most prevalent cancer among males. The massive survivorship indicates that the treatment of PCa is an encouraging cancer research direction [3]. Mortality, and survivorship, there is an urgent need for novel drugs that can radically cure PCa, especially the hormone-refractory PCa. Lycorine, a medicinal plant-derived phenanthridine Amaryllidaceae alkaloid [4], seems to possess such properties for PCa drug research and development
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
